A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

The Trump administration is considering a proposal to allow Medicare and Medicaid to cover expensive weight-loss drugs. GLP-1 ...

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...